Pharmacology

Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister Fluid

Dana Maglio, Renli Teng, Per T. Thyrum, Charles H. Nightingale, David P. Nicolau
DOI: 10.1128/AAC.47.5.1771-1773.2003

Article Information

DOI 
https://doi.org/10.1128/AAC.47.5.1771-1773.2003
PubMed 
12709358
Published By 
American Society for Microbiology Journals
History 
  • Received September 12, 2002
  • Returned for modification January 21, 2003
  • Accepted February 10, 2003
  • Published online May 1, 2003.
Copyright & Usage 
Copyright © 2003 American Society for Microbiology

Author Information

  1. Dana Maglio1,
  2. Renli Teng2,
  3. Per T. Thyrum2,
  4. Charles H. Nightingale3 and
  5. David P. Nicolau1,4*
  1. 1Center for Anti-Infective Research and Development
  2. 4Division of Infectious Diseases
  3. 3Office for Research, Hartford Hospital, Hartford, Connecticut 06102
  4. 2AstraZeneca Pharmaceuticals, Wilmington, Delaware 19803
  • ↵* Corresponding author. Mailing address: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour St., Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-3992. E-mail: dnicola{at}harthosp.org .

Article usage

Article usage: to

Rendering graph...
AbstractFullPdf
Back to top
Download PDF
Citation Tools
Print

Alerts
Email

KEYWORDS

Blister
Cantharidin
Thienamycins

Related Articles

Cited By...